Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

Description

Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.

Conditions

Glaucoma, Ocular Hypertension, Open Angle Glaucoma

Study Overview

Study Details

Study overview

Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

Condition
Glaucoma
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. 18 years old or older
  • 2. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT)
  • 3. Use of prostaglandin analogue (PGA) eye drop
  • 4. Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months)
  • 1. Uncontrolled glaucoma
  • 2. Have had eye surgery (including laser procedures) within the past six months
  • 3. Have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases
  • 4. Use of non-PGA class of IOP-lowering medication

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Julius Oatts, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2024-12-10